U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Prurigo Nodularis

; ; ; .

Author Information and Affiliations

Last Update: September 12, 2022.

Continuing Education Activity

Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The diagnosis is chiefly clinical. However, lichen simplex chronicus and hypertophic lichen planus may be clinically indistinguishable in many cases. Thus diagnostic confirmation with dermoscopy and histopathology becomes important. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important. This activity reviews the evaluation and management of prurigo nodularis, and highlights the role of the interprofessional team in caring for patients with this condition.

Objectives:

  • Identify the etiology of prurigo nodularis.
  • Describe the evaluation of prurigo nodularis.
  • List the treatment and management options available for prurigo nodularis.
  • Employ interprofessional team strategies to improve care coordination and care delivery for patients with prurigo nodularis.
Access free multiple choice questions on this topic.

Introduction

Prurigo nodularis (PN) is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and the condition may occur in any age group. It is commonly associated with another disorder of cutaneous hypersensitivity such as atopic dermatitis or chronic pruritus of diverse origins. The diagnosis is mainly clinical; although certain conditions may simulate it clinically warranting differentiation. The condition is associated with significant physical and psychological morbidity and often refractory to treatments. A whole range of general measures, pharmacological approaches and psychological therapies may be needed in a patient with advanced PN. [1][2][3][4]

Etiology

The exact etiology of prurigo nodularis remains poorly understood. Although the role of unimpeded itch-scratch cycle is uncontested, the exact sequence of events leading to the final clinical picture remain conjectural.  Prurigo nodularis is accompanied by long-standing pruritus and thought to develop as a reaction to repeated scratching in patients with chronic prurigo of various etiologies including dermatological, systemic, infectious, and neuropsychiatric[5][6].

Anecdotal data suggests causative role or association of infectious agents such as hepatitis C, Helicobacter pylori, Strongyloides stercoralis, mycobacteria and HIV in PN [7] [8]

Increase in the number of sensory structures of the epidermis (merkel cells) and dermis (papillary dermal nerves) is encountered in PN lesions [9]. This neural alteration is typical of PN and not seen in lichen simplex chronicus or neurodermatitis. 

The density of mast cells and neutrophils is increased in PN although there seems to be no increase in their degranulation products. In contrast while the number of eosinophils remains maintained, their products such as the major basic protein and eosinophil-derived neurotoxin show higher than normal levels.

The pruritus in PN seems to be a result of cutaneous neurogenic inflammation mediated by various neuropeptides especially substance P, calcitonin gene–related peptide (CGRP) [10], and vanilloid receptor subtype 1 (VR-1). The latter binds to capsaicin, rendering it a potential therapeutic topical agent.

Individuals with PN also show elevated levels of Interleukin 31(IL-31), a T-cell–derived highly prurigogenic cytokine [11].

Epidemiology

The exact incidence of PN is not known. A majority of patients with PN present between the ages of 51 and 65 years, although several cases in other age groups have also been described [5][12]. While the disease afflicts both genders, it seems to be more frequent and more intense in females[13]. Multiple studies have shown that individuals with an atopic predisposition have an earlier age of onset[5][14][15]. Ethnicity and genetic predisposition seem to play a role since individuals belonging to the African-American ethnic group are 3.4 times more likely to have prurigo nodularis than white patients[12]. Other conditions that have been reported to induce prurigo nodularis include internal malignancy, renal failure, and psychiatric conditions. In HIV positive patients, PN has been reported to be predictive of advanced immunosuppression[16]

Pathophysiology

The pathophysiology of PN has been controversial [vide supra]. Chronic and/or recurrent mechanical trauma or vigorous frictional assault to the skin induced epidermal hyperplasia with resultant thickening of the skin. Repetitive mechanical rubbing/scratching not only result in the formation of plaques and nodules, often with lichenification; but also give rise to dyschromic changes, typically hyperpigmentation. The itching of PN is typically episodic, severe, and uncontrollable and tends to occur at discrete points that eventually transform into hyperpigmented noduloplaques with excoriations, crusting and sometimes secondary bacterial infection.

Immunohistochemical studies have shown an increased number of dermal nerve fibres in the papillary dermis. It has been postulated that the thin, unmyelinated epidermal nerves are the transmitters of the severe prurigo.  Nerve growth factor (NGF) and its receptor, tyrosine receptor kinase A (TrkA), are overexpressed in PN lesions. They may also be associated with the increased release and accumulation of neuropeptides, such as substance P and calcitonin gene-related peptide [17]. Interestingly, skin biopsies taken from lesions of PN tend to show significantly decreased intraepidermal (not dermal) nerve fiber density. Although this finding raised the doubt of some subclinical small nerve fibre neuropathy contributing to the pathophysiology, recent studies have suggested that this reduction may actually be secondary to chronic scratching. This was confirmed on observing restoration of the intraepidermal nerve fiber density on complete healing of lesions [18].  

The role of helper T cytokines, T helper 1 and T helper 2, have also been studied in the pathogenesis of prurigo nodularis using the signal transducers and activators of transcription (STAT) 1, 3, and 6. In every case examined but three, the entire epidermis stained with anti-pSTAT 6, a marker for the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13. These findings suggest that Th2 cytokines play a principal role in the pathogenesis of prurigo nodularis.[19] 

Histopathology

Lesions of prurigo nodularis under histopathology can show thick, orthohyperkeratosis, irregular epidermal hyperplasia, and pseudoepitheliomatous hyperplasia. Focal parakeratosis with irregular acanthosis diminished nerve fiber density and a nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils may also be seen on histology for prurigo nodularis lesions. Histology can play an important role in diagnosing prurigo nodularis vs. lichen simplex and hypertrophic lichen planus. Lesions of lichen simplex are less likely to have pseudoepitheliomatous hyperplasia or nerve fiber thickening; however, it does not rule out the histological diagnosis of PN. It is necessary to correlate clinical and histological findings together to reliably distinguish between PN and LS[20]. HLP and PN both demonstrate epidermal hyperplasia, hypergranulosis, and compact hyperkeratosis. Vertically arranged collagen fibers and an increased number of fibroblasts and capillaries in the dermis are found in both conditions. However, basal cell degeneration is limited to the tips of rete ridges, and no band-like inflammation will be seen in HLP vs. PN[21]

History and Physical

Patients with prurigo nodularis present with a characteristic firm, dome-shaped, pruritic nodules that vary in size from a few millimeters to centimeters. The nodules can be flesh-colored, erythematous, pink, and brown/black. Initially, the lesions can begin as normal skin or areas of xerosis. Due to pruritus, the patients will begin and continue to scratch the lesions until the dome-shaped nodule forms. Typically, the lesions are found symmetrically on the patient’s extensor surfaces of the arm and legs[22]. Lesions can also be found in the occipital region of the scalp. The upper back, abdomen, and sacrum also can be involved. Usually, areas that are difficult to reach such as the upper mid-back are spared. This finding is called the “butterfly sign.” The palms, soles, face, and flexural areas are usually spared. There is associated with severe pruritus that can be very distressing for the patients with prurigo nodularis. It can be sporadic or continuous and can increase with sweating, clothing irritation, or heat. Patients experience a combination of pruritic sensations including burning, stinging, and alterations in lesional temperature.[5] It has been reported that in some cases, atopic dermatitis and xerosis are found in conjunction with prurigo nodularis and may be the initiating factor. Lesions can often appear excoriated due to the pruritus involved with PN. Excoriated lesions are at increased risk of secondary infection and can appear crusted, erythematous or painful if infected. Prurigo nodularis can also be localized in the setting of an underlying local dermatosis such as venous stasis, postherpetic neuralgia, or brachioradial pruritus. [23]

Evaluation

Prurigo nodularis is a clinical diagnosis. Prurigo nodularis patients will likely have a history of chronic severe pruritus with excoriations and flesh-colored, pink nodular lesions on extensor surfaces. Dermoscopy can be a helpful tool when diagnosing PN vs. HLP. In one study, dermoscopy of HLP demonstrated pearly white areas and peripheral striations, gray-blue globules comedo-like openings, red dots and globules, brownish-black globules and yellowish structures. In PN, red dots and globules and pearly white areas with peripheral striations were observed under dermoscopy[24]. A skin biopsy may be warranted for lesions that are bleeding, have formed ulcers or are resistant to first-line therapies. If patients with prurigo nodularis and severe pruritus do not have a cause of the pruritus, causes of chronic pruritus should be evaluated. Causes of severe pruritus can include renal disease, liver disease, thyroid disease, HIV infection, malignancy or parasitic infection[25]. Evaluation of these causes includes a complete blood cell count (CBC), complete metabolic panel, thyroid studies including TSH and free T4, urinalysis, stool exam, HIV antibodies, and chest x-ray. Serum IgE levels can also be elevated in patients with PN and atopic dermatitis[26].

Treatment / Management

Management of prurigo nodularis requires a multifaceted approach. Patients need to be educated on practices to reduce scratching of lesions, assurance and diagnosing of underlying causes of pruritus and diagnosis and treatment of any psychological disorder associated with scratching and picking at skin. Treatments, both topical and systemic, are targeted at disrupting the itch-scratch cycle.

GENERAL CARE

  • Patients are encouraged to keep their nails short, wear protective clothing such as long sleeves and gloves, and to keep the nodules covered with bandages. 
  • Using gentle cleansers to bathe and applying emollients multiple times a day to keep skin moisturized should be encouraged.
  • Calamine lotions and lotions containing menthol and camphor can provide relief from the pruritus.
  • Stay in a cool comfortable environment.
  • Reduce stress. 

SPECIFIC CARE

TOPICAL AND INTRALESIONAL THERAPY

  • Although none have been examined in randomized trials, topical treatments for prurigo nodularis include class one topical corticosteroids, intralesional corticosteroids, topical calcineurin inhibitors, topical capsaicin, and topical vitamin D analogs.
  • First-line therapy is suggested to be topical corticosteroids, such as clobetasol dipropionate 0.05% ointment applied under occlusion with plastic wrap once at nighttime for at least two to four weeks.
  •  Triamcinolone acetonide in concentrations of 10 mg/mL to 20 mg/mL injected intralesionally has been shown to flatten lesions and provide relief from pruritus. [27][28][29][30][31]
  • Pimecrolimus 1% is as effective as hydrocortisone and can be implemented in a long-term regimen.[32]
  • Calcipotriol ointment shows greater efficacy as compared to betamethasone valerate 0.1%.[33]
  • The menthol in low concentration ( less than 5% ) alleviates pruritus by heightening the threshold for pruritic stimuli.[34]

ANTIHISTAMINES AND LEUKOTRINE INHIBITORS

  • High dose non sedating antihistamines for daytime followed by First-generation sedating antihistamines at bedtime. A combination of fexofenadine and montelukast gives good results.[35]Common adverse reactions to antihistamines are drowsiness, dizziness, and weakness. 

PHOTOTHERAPY/EXCIMER

  • Phototherapy with PUVA, including bath/topical PUVA, long-wavelength ultraviolet A, narrowband ultraviolet B, and monochromatic excimer light of 308 nm, have been used and shown improvement of prurigo nodularis nodules in patients.
  • Narrow Band UVB phototherapy results in significant improvement in prurigo nodularis at an average dose of 23.88- 26.00 j/cm2.[36]
  • An excimer laser is more beneficial than topical clobetasol.[37]

 ORAL IMMUNOSUPPRESSIVES

  • As with topical therapies, no randomized trials have been reported involving the use of these systemic therapies and the benefits versus risks of the drugs must be considered before beginning treatment[13]
  • Oral immunosuppressive therapy should be considered for patients with severe, recalcitrant prurigo nodularis.
  • A single-institution retrospective study demonstrated clinical improvement and a decrease in pruritus with Cyclosporine at a mean dose of 3.1 mg/kg dose.[38]
  • Methotrexate in a dose of 5-20mg/kg weekly demonstrated complete or partial remission of 2.4 months. These patients showed a mean duration of response of 19 months.[39]
  • Treatment with azathioprine and cyclophosphamide has also been reported to be successful.[40][41]
  • Oral tacrolimus therapy dramatically reduced pruritus in a patient who was previously treated with cyclosporine for prurigo nodularis.[42]
  • Combination therapy of three cycles of intravenous immunoglobulin followed by methotrexate and topical steroid was effective in prurigo nodularis associated with atopic dermatitis.[43]

NOVEL TREATMENTS

  • Thalidomide and Lenalidomide. Thalidomide is an immunomodulatory agent, which also acts as a central and peripheral depressant, and inhibits tumor necrosis factor-alpha.[43] The therapeutic effect against prurigo nodularis is thought to derive from its neurotoxic effects.[44] Lenalidomide, a more potent molecular form of thalidomide, is effective in prurigo nodularis and has a lower frequency of peripheral neuropathy.[45]
  • Both selective serotonin reuptake inhibitors and tricyclic antidepressants can also be considered for chronic pruritus. It is important for patients to also be seen in conjunction with mental health professionals. 
  • Naloxone and naltrexone exert antipruritic effect through inhibition of Mu-opioid receptors on nociceptive neurons and interneurons resulting in suppression of itch.[46]
  • NK1r antagonists, aprepitant and serlopitant, could prevent substance P mediated signaling in the pathogenesis of prurigo nodularis[47]. Significant relief of itch was achieved in prurigo nodularis patients on aprepitant monotherapy.
  • IL 31 receptor antibody, Nemolizumab, provided significant improvement in pruritus scores in patients with moderate to severe atopic dermatitis. However, its role in prurigo nodularis remains unclear.

Differential Diagnosis

  • Lichen simplex chronicus 
  • Hypertrophic lichen planus
  • Pemphigoid nodularis
  • Nodular scabies
  • Keloids
  • Dermatofibroma
  • Foreign body reactions

Treatment Planning

Treatment of prurigo nodularis should be tailored to the patient's age, comorbidities, the severity of prurigo, quality of life and expected side effects.

First Line

  • Class 1 topical steroids ( Clobetasol propionate 0.05%, halobetasol propionate 0.05%) Long term applications can lead to adverse effects like skin atrophy, folliculitis, miliaria, delayed wound healing, tachyphylaxis.
  • Intralesional injections of triamcinolone acetonide (40mg/ml). This may be accompanied by cryotherapy.[48][49]
  • Topical menthol solution in a concentration of less than 5%.
  • Systemic antihistamines: fexofenadine 180mg, levocetirizine 5mg or desloratadine 5mg during daytime and sedating antihistamines like hydroxizine25mg at night time. The first generation antihistamines cause side effects like sedation, hyperexcitability, impaired cognitive function, dry mouth, constipation, dysuria, tachycardia, and arrhythmias.

Second-line

  • Phototherapy: PUVA, long-wavelength UVA, Narrowband UVB, monochromatic excimer light of 308nm
  • Systemic immunosuppressives: Cyclosporine 3mg/kg daily. Adverse effects include nephrotoxicity, hypertension, hyperlipidemia, hyperkalemia, hyperuricemia. Methotrexate 5-20mg/week. Common adverse effects are nausea, gastrointestinal symptoms, and transaminitis.
  • Thalidomide 300-400 mg daily yields good response within 3 months, followed by tapering the dose to 50mg daily. However, complete cessation of the drug leads to recurrences. Adverse effects are teratogenicity and peripheral neuropathy. Lenalidomide 5-10mg daily is less neurotoxic than thalidomide.
  • Opioid receptor antagonists : Naltrexone 50mg daily. Adverse effects are restricted to the first 2 weeks of treatment and include nausea, fatigue, dizziness, heartburn, and diarrhea. 

Prognosis

Prurigo nodularis is a benign condition with a good prognosis. It is a chronic condition, typically preceded by an underlying cause of pruritus. However, prurigo nodularis is a distinct entity from these underlying causes and can persist despite the resolution of the predisposing condition. 

Complications

Lesions of prurigo nodularis can become secondarily infected due to scratching of the lesions. It is important to monitor for clinical signs of infection such as erythema, pain, warmth and fever. If secondary infection is suspected, it is important to begin appropriate topical or systemic antibiotic therapy to cover for skin flora. 

Deterrence and Patient Education

The deterrents in prurigo nodularis treatment are the severe intensity of the itch which can lead to psychological distress, chronic nature of the condition, the long duration of the therapy and the potential side effects of the medication.

Discussion with the patient should include advantages and disadvantages of the therapy, side effects and possible use of off-label medications. Patient education can thus promote treatment adherence. The potential length of therapy should also be discussed as prurigo nodularis is difficult to treat and the patient may become frustrated with lack of improvement.

Pearls and Other Issues

Prurigo nodularis is a chronic skin disease that can cause a significant impact on a patients quality of life. Breaking the itch-scratch cycle requires a multifaceted approach and patients should be encouraged to continue with therapy to reduce scratching and picking at the lesions. It may be necessary to involve behavioral therapy if required. It is important to explain to patients that prurigo nodularis lesions may be chronic and very difficult to improve completely.

Enhancing Healthcare Team Outcomes

Management of prurigo nodularis requires an interprofessional team that includes the primary caregiver, nurse practitioner, dermatologist, and a mental health nurse. Patients need to be educated on practices to reduce scratching of lesions, assurance and diagnosing of underlying causes of pruritus and diagnosis and treatment of any psychological disorder associated with scratching and picking at skin. Treatments, both topical and systemic, are targeted at disrupting the itch-scratch cycle. Patients are encouraged to keep their nails short, wear protective clothing such as long sleeves and gloves, and to keep the nodules covered with bandages. Using gentle cleansers to bathe and applying emollients multiple times a day to keep skin moisturized should be encouraged. Calamine lotions and lotions containing menthol and camphor-like Sarna can provide relief from the pruritus. First-generation sedating antihistamines such as hydroxyzine administered at bedtime may be useful in controlling nocturnal pruritus. Both selective serotonin reuptake inhibitors and tricyclic antidepressants can also be considered for chronic pruritus. [12]

Finally, the pharmacist should educate the patient on potential adverse reactions of the medications and report back to the clinical team if there are complications.

Review Questions

Image

Figure

Prurigo Nodularis DermNet New Zealand

Figure 1 PRURIGO NODULARIS involving the limbs of a 65-year old lady: A, Clinical Image showing the typical hyperpigmented papules and nodules over the right upper extremity with excoriations; B, Polarized dermoscopic image from a papule showing an irregularly-shaped large reddish-brown clod with localized white structureless area (white arc), with interspersed red and brown colored dots and pigmented granules [Escope, USB Videodermoscope, 30X; Timpac Healthcare Pvt

Figure

Figure 1 PRURIGO NODULARIS involving the limbs of a 65-year old lady: A, Clinical Image showing the typical hyperpigmented papules and nodules over the right upper extremity with excoriations; B, Polarized dermoscopic image from a papule showing an irregularly-shaped (more...)

Prurigo Nodularis Contributed by Dr

Figure

Prurigo Nodularis Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India

References

1.
Harbaoui S, Litaiem N. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 13, 2023. Acquired Perforating Dermatosis. [PubMed: 30969537]
2.
Larson VA, Tang O, Stander S, Miller LS, Kang S, Kwatra SG. Association between prurigo nodularis and malignancy in middle-aged adults. J Am Acad Dermatol. 2019 Nov;81(5):1198-1201. [PMC free article: PMC7377235] [PubMed: 30954580]
3.
Ständer S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, Luger TA., TCP-102 Study Group. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019 May;80(5):1395-1402. [PubMed: 30894279]
4.
Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163-172. [PMC free article: PMC6400231] [PubMed: 30881076]
5.
Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013 May;27(5):550-7. [PubMed: 22364653]
6.
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo--a clinicopathological study of 46 patients. Br J Dermatol. 1985 Oct;113(4):431-9. [PubMed: 4063179]
7.
Mattila JO, Vornanen M, Vaara J, Katila ML. Mycobacteria in prurigo nodularis: the cause or a consequence? J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):224-8. [PubMed: 8642086]
8.
Jacob CI, Patten SF. Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus. J Am Acad Dermatol. 1999 Aug;41(2 Pt 2):357-61. [PubMed: 10426933]
9.
Nahass GT, Penneys NS. Merkel cells and prurigo nodularis. J Am Acad Dermatol. 1994 Jul;31(1):86-8. [PubMed: 7517411]
10.
Vaalasti A, Suomalainen H, Rechardt L. Calcitonin gene-related peptide immunoreactivity in prurigo nodularis: a comparative study with neurodermatitis circumscripta. Br J Dermatol. 1989 May;120(5):619-23. [PubMed: 2474315]
11.
Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006 Feb;117(2):411-7. [PubMed: 16461142]
12.
Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S, Kang S, Kwatra SG. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018 Oct;79(4):714-719.e3. [PMC free article: PMC6518410] [PubMed: 29733939]
13.
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatolog Treat. 2013 Dec;24(6):458-62. [PubMed: 23767411]
14.
Tanaka M, Aiba S, Matsumura N, Aoyama H, Tagami H. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology. 1995;190(4):269-76. [PubMed: 7655104]
15.
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatology. 2014;228(3):276-80. [PubMed: 24662043]
16.
Magand F, Nacher M, Cazorla C, Cambazard F, Marie DS, Couppié P. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg. 2011 Jul;105(7):401-4. [PubMed: 21621233]
17.
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol. 2005 Nov;46(4):211-18; quiz 219-20. [PubMed: 16197418]
18.
Pereira MP, Mühl S, Pogatzki-Zahn EM, Agelopoulos K, Ständer S. Intraepidermal Nerve Fiber Density: Diagnostic and Therapeutic Relevance in the Management of Chronic Pruritus: a Review. Dermatol Ther (Heidelb). 2016 Dec;6(4):509-517. [PMC free article: PMC5120635] [PubMed: 27730494]
19.
Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011 Nov;165(5):990-6. [PubMed: 21711341]
20.
Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol. 2010 May;37(5):578-86. [PubMed: 20002240]
21.
Ankad BS, Beergouder SL. Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. Dermatol Pract Concept. 2016 Apr;6(2):9-15. [PMC free article: PMC4866621] [PubMed: 27222766]
22.
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. [PubMed: 18358109]
23.
Pereira MP, Lüling H, Dieckhöfer A, Steinke S, Zeidler C, Ständer S. Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies. Acta Derm Venereol. 2018 Jan 12;98(1):82-88. [PubMed: 28902951]
24.
Nair PA, Patel T. Dermatoscopic Features of Prurigo Nodularis. Indian Dermatol Online J. 2019 Mar-Apr;10(2):187-189. [PMC free article: PMC6434741] [PubMed: 30984602]
25.
Nowak DA, Yeung J. Diagnosis and treatment of pruritus. Can Fam Physician. 2017 Dec;63(12):918-924. [PMC free article: PMC5729138] [PubMed: 29237630]
26.
Przybilla B, Ring J, Völk M. [Total IgE levels in the serum in dermatologic diseases]. Hautarzt. 1986 Feb;37(2):77-82. [PubMed: 3957665]
27.
Katayama C, Hayashida Y, Sugiyama S, Shiohara T, Aoyama Y. Corticosteroid-resistant prurigo nodularis: a rare syringotropic variant associated with hypohidrosis. Eur J Dermatol. 2019 Apr 01;29(2):212-213. [PubMed: 30827950]
28.
Legat FJ. The Antipruritic Effect of Phototherapy. Front Med (Lausanne). 2018;5:333. [PMC free article: PMC6287194] [PubMed: 30560129]
29.
Gupta MA, Pur DR, Vujcic B, Gupta AK. Use of antiepileptic mood stabilizers in dermatology. Clin Dermatol. 2018 Nov-Dec;36(6):756-764. [PubMed: 30446200]
30.
Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2019 Jan 01;155(1):118-120. [PubMed: 30427994]
31.
Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019 Mar;80(3):756-764. [PubMed: 30261199]
32.
Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, Augustin M, Luger TA, Ständer S. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology. 2013;227(4):353-60. [PubMed: 24281309]
33.
Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol. 2000 Jun;136(6):807-8. [PubMed: 10871962]
34.
Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007 Nov;57(5):873-8. [PubMed: 17498839]
35.
Shintani T, Ohata C, Koga H, Ohyama B, Hamada T, Nakama T, Furumura M, Tsuruta D, Ishii N, Hashimoto T. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther. 2014 May-Jun;27(3):135-9. [PubMed: 24102897]
36.
Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):799-803. [PubMed: 20946583]
37.
Brenninkmeijer EE, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010 Oct;163(4):823-31. [PubMed: 20491772]
38.
Wiznia LE, Callahan SW, Cohen DE, Orlow SJ. Rapid improvement of prurigo nodularis with cyclosporine treatment. J Am Acad Dermatol. 2018 Jun;78(6):1209-1211. [PubMed: 29438756]
39.
Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):437-440. [PubMed: 29055135]
40.
Lear JT, English JS, Smith AG. Nodular prurigo responsive to azathioprine. Br J Dermatol. 1996 Jun;134(6):1151. [PubMed: 8763446]
41.
Gupta R. Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):239. [PubMed: 26924412]
42.
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm Venereol. 2015 Sep;95(7):866-7. [PubMed: 25804254]
43.
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis responds to intravenous immunoglobulins. Br J Dermatol. 2012 Feb;166(2):461-2. [PubMed: 21910702]
44.
Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin. 2010 Jul;28(3):577-86. [PubMed: 20510766]
45.
Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol. 2012 Jul;148(7):794-6. [PubMed: 22801610]
46.
Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012 Sep;92(5):555-60. [PubMed: 22504709]
47.
Haas S, Capellino S, Phan NQ, Böhm M, Luger TA, Straub RH, Ständer S. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci. 2010 Jun;58(3):193-7. [PubMed: 20417061]
48.
Waldinger TP, Wong RC, Taylor WB, Voorhees JJ. Cryotherapy improves prurigo nodularis. Arch Dermatol. 1984 Dec;120(12):1598-600. [PubMed: 6508332]
49.
Stoll DM, Fields JP, King LE. Treatment of prurigo nodularis: use of cryosurgery and intralesional steroids plus lidocaine. J Dermatol Surg Oncol. 1983 Nov;9(11):922-4. [PubMed: 6630706]

Disclosure: Tessa Mullins declares no relevant financial relationships with ineligible companies.

Disclosure: Poonam Sharma declares no relevant financial relationships with ineligible companies.

Disclosure: Christopher Riley declares no relevant financial relationships with ineligible companies.

Disclosure: Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK459204PMID: 29083653

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...